Our Programs

Tiburio is advancing a pipeline of Phase 2 ready assets

Tiburio is advancing a pipeline of Phase 2 ready assets

Tiburio’s clinical stage pipeline is based on novel dopamine-somatostin chimeric molecules for the treatment of severe neuroendocrine disorders. This unique class of chimeric compounds combines structural elements of both dopamine and somatostatin giving them the ability to bind and activate both receptors. Studies suggest that these chimeric compounds may facilitate physical interactions between dopamine and somatostatin receptors that results in enhanced activity, offering new potential for a variety of diseases with unmet need.

CompoundPreclinicalPhase 1Phase 2Phase 3
TBR-760

For treatment of NFPA.

Preclinical
Phase 1
Phase 2
Phase 3
TBR-065

For treatment of rare endocrine disorders.

Preclinical
Phase 1
Phase 2
Phase 3